PC
GEVA

PointState Capital’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

PointState Capital’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-170,000
Closed -$10.8M – 190
2013
Q3 		$10.8M Buy
+170,000
New +$8.37M 0.18% 77

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PointState Capital's GEVA Position: Q4 2013 in Review

PointState Capital sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2013, closing a stake of 170,000 shares — an estimated $10.8M sold.

PointState Capital first reported a position in GEVA in Q3 2013 and held it in 1 quarter. The position peaked at $10.8M in Q3 2013. 84 funds tracked by Wall St. Rank hold GEVA as of Q4 2013.

  • PointState Capital reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • PointState Capital sold 170,000 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2013, an estimated $10.8M.
  • PointState Capital first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 1 quarter.
  • PointState Capital's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $10.8M in Q3 2013.
  • 84 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2013.

Based on PointState Capital's 13F filing for Q4 2013, filed 14 Feb 2014.